Stocktoria
LABCORP HOLDINGS INC. LH
LABCORP HOLDINGS INC. (LH) earns a Piotroski F-score of 8/9 (strong financial health), with an Altman Z″ in the safe zone. It pays a dividend yielding 1.08% (safety: safe). FY2025 revenue was $14.0B at a 6.3% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.56 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-08-04 | Piper Sandler | Neutral (main) |
| 2026-08-03 | JP Morgan | Overweight (main) |
| 2026-07-31 | Morgan Stanley | Overweight (main) |
| 2026-07-31 | Truist Securities | Buy (main) |
| 2026-07-31 | Barclays | Equal-Weight (main) |
| 2026-07-13 | B of A Securities | Buy (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 8/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.065 |
| Retained earnings / assets | 0.47 |
| EBIT / assets | 0.075 |
| Equity / liabilities | 0.884 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| LH | LABCORP HOLDINGS INC. | 8/9 | 3.39 | 25.4 | +7.2% |
| DGX | QUEST DIAGNOSTICS INC | 7/9 | 3.53 | 23.4 | +11.8% |
| FTRE | Fortrea Holdings Inc. | 3/9 | -3.58 | — | +1% |
| NTRA | Natera, Inc. | 3/9 | 0.87 | — | +35.9% |
| RDNT | RadNet, Inc. | 3/9 | 1.4 | — | +11.5% |
| GH | Guardant Health, Inc. | 4/9 | -2.57 | — | +32.9% |
| VCYT | VERACYTE, INC. | 7/9 | 15.66 | 61.2 | +16% |
About LABCORP HOLDINGS INC.
Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing service, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, it offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI enabled Test Selection, a generative AI enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. It has a strategic collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics; and Alliance for Clinical Trials in Oncology to advance national clinical trial for patients diagnosed with colorectal cancer. The company was founded in 1995 and is headquartered in Burlington, North Carolina.
FAQ
Is LH financially healthy?
LABCORP HOLDINGS INC.'s Piotroski F-score is 8/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does LH pay a dividend, and is it safe?
Yes. LABCORP HOLDINGS INC. pays a dividend yielding about 1.08% with a 27.5% payout ratio, rated “safe” for safety.
How profitable is LH?
In FY2025, LABCORP HOLDINGS INC. had a net margin of 6.3% and a return on equity of 10.2%.
Is LH overvalued or undervalued?
LABCORP HOLDINGS INC. trades at about 30.9× trailing earnings — above its 10-year norm (10-year range 9.6×–46.6×, median 16.9×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for LH?
The average Wall-Street price target for LABCORP HOLDINGS INC. is $337.75, about 4.4% above the recent price, from 16 analysts (consensus: buy).
Is LH a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on LABCORP HOLDINGS INC.: a Piotroski F-score of 8/9, an Altman Z″ in the safe zone, a P/E of about 25.4×, a dividend yield of 1.08%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.